ProKidney Corp. (PROK)
- Previous Close
3.1900 - Open
3.3100 - Bid 2.9100 x 200
- Ask 3.0500 x 500
- Day's Range
2.4809 - 3.4301 - 52 Week Range
1.1200 - 13.5100 - Volume
2,925,474 - Avg. Volume
827,920 - Market Cap (intraday)
1.806B - Beta (5Y Monthly) 1.40
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5700 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.33
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
www.prokidney.comRecent News: PROK
Performance Overview: PROK
Trailing total returns as of 6/10/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PROK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PROK
Valuation Measures
Market Cap
193.69M
Enterprise Value
-129.36M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
2.13
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-21.34%
Return on Equity (ttm)
-31.72%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-35.3M
Diluted EPS (ttm)
-0.5700
Balance Sheet and Cash Flow
Total Cash (mrq)
329M
Total Debt/Equity (mrq)
1.64%
Levered Free Cash Flow (ttm)
-85.9M
Research Analysis: PROK
Company Insights: PROK
PROK does not have Company Insights